Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 11 of 99

  1. AG-181

    Agios Netherlands B.V.

    Phenylketonuria

    phase 1 small molecule active

    1 trial

  2. AG-236

    Agios Netherlands B.V.

    Healthy Participants

    phase 1 small molecule active

    1 trial

  3. AG-348

    Agios Netherlands B.V.

    Sickle Cell Disease

    phase 1 small molecule completed

    1 trial

  4. AG-348

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  5. AG-348

    Agios Netherlands B.V.

    Healthy Volunteer

    phase 1 small molecule completed

    2 trials

  6. AG-348

    Agios Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  7. AG-348 Sequence A

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  8. AG-519

    Agios Netherlands B.V.

    Anemia

    phase 1 small molecule terminated

    1 trial

  9. AG-636

    Agios Netherlands B.V.

    Lymphoma

    phase 1 small molecule terminated

    1 trial

  10. AG-881

    Agios Netherlands B.V.

    Healthy Male Participants

    phase 1 small molecule completed

    1 trial

  11. AG-881

    Agios Netherlands B.V.

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  12. AG-946

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. AG10 oral tablet

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy, Transthyretin-Related

    phase 1 small molecule completed

    1 trial

  14. AG120

    Agios Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    2 trials

  15. AG120-221-C-001

    The George Institute

    Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    phase 1 other active

    1 trial

  16. AG120-C-001

    The George Institute

    AG-120 is being investigated for the treatment of patients with advanced hematologic malignancies that are IDH1 mutation.

    phase 1 other active

    1 trial

  17. AG221

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  18. AG881

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. AG881

    Agios Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule completed

    1 trial

  20. AG881 Formulation 1

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. AGMB-129

    Agomab Therapeutics NV

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  22. AGMB-447

    Agomab Therapeutics NV

    IPF

    phase 1 small molecule active

    1 trial

  23. AGMB101-01-CL-102

    Agomab Therapeutics NV

    liver cirrhosis

    phase 1 other active

    1 trial

  24. AGMB129-01-CL-109

    Agomab Therapeutics NV

    Fibrostenotic Crohn’s disease

    phase 1 other active

    1 trial

  25. AIR DNase

    Protalix BioTherapeutics

    Cystic Fibrosis (CF)

    phase 1 small molecule completed

    1 trial

  26. AK120 or placebo- Part 1- Cohort 1

    Akeso

    Atopic Dermatitis

    phase 1 small molecule completed

    1 trial

  27. AKB-6548

    Akebia Europe Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  28. AKB-6548 (therapeutic dose)

    Akebia Europe Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  29. AKB-6548-CI-0013

    Akebia Europe Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  30. AKB-9090

    Akebia Europe Limited

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  31. ALG-000184

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  32. ALG-010133

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  33. ALG-020572

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  34. ALG-055009

    Aligos Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  35. ALG-055009

    Aligos Therapeutics

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  36. ALG-097558

    Aligos Therapeutics

    COVID-19

    phase 1 small molecule completed

    3 trials

  37. ALG-125755

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  38. ALKS 33-BUP

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 1 small molecule completed

    1 trial

  39. ALLO-316

    Allogene Therapeutics

    Advanced/Metastatic Clear Cell Renal Cell Carcinoma

    phase 1 gene therapy active

    1 trial

  40. ALLO-329

    Allogene Therapeutics

    Systemic Lupus Erythematosus (With and Without Nephritis)

    phase 1 gene therapy active

    1 trial

  41. ALLO-501

    Allogene Therapeutics

    Relapsed/Refractory Large B Cell Lymphoma

    phase 1 gene therapy completed

    1 trial

  42. ALLO-715

    Allogene Therapeutics

    Relapsed/Refractory Multiple Myeloma

    phase 1 gene therapy completed

    1 trial

  43. ALN-4285

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  44. ALN-4915

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  45. ALN-5288

    Alnylam Netherlands B.V.

    Alzheimer's Disease

    phase 1 small molecule active

    1 trial

  46. ALN-5288-001

    Alnylam Netherlands B.V.

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  47. ALN-AAT

    Alnylam Netherlands B.V.

    Antitrypsin Deficiency Liver Disease

    phase 1 small molecule terminated

    1 trial

  48. ALN-AGT01

    Alnylam Netherlands B.V.

    Hypertension

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.